Lab-on-a-Chip, Microfluidics, & Organ-on-a-Chip Asia 2024 Agenda

Title to be Confirmed.
Ryuji Yokokawa, Professor, Department of Micro Engineering, Kyoto University, Japan

Title to be Confirmed.
Lydia Sohn, Almy C. Maynard and Agnes Offield Maynard Chair in Mechanical Engineering, University of California-Berkeley, United States of America

Title to be Confirmed.
Noah Malmstadt, Professor, Mork Family Dept. of Chemical Engineering & Materials Science, University of Southern California, United States of America

Title to be Confirmed.
Hiroshi Kimura, Professor, Micro/Nano Technology Center, Tokai University, Japan

Title to be Confirmed.
Nancy Allbritton, Frank and Julie Jungers Dean of the College of Engineering and Professor of Bioengineering, University of Washington in Seattle, United States of America

Nanoscale Electrokinetics Empowers Mechano Phenotyping of Single Cells
Hirofumi Shintaku, Professor, Institute for Life and Medical Sciences, Kyoto University, Japan

Nanopore electroporation uses nanostructures to create focused electric fields, which form pores in lipid bilayers of living cells with low invasiveness. We introduce ELASTomics, an approach that parallelly profile cell surface tension and gene expression of thousands of single cells leveraging nanopore electroporation and single-cell RNA-sequencing. We show that our system dissects the heterogeneity in cellular mechanics and uncovers the transcriptomic regulatory mechanism in cancer malignancy, cell differentiation, and cellular senescence.

Microphysiological System for Disease Modeling and Drug Testing
Jessie Jeon, Associate Professor, KAIST, Korea South

3D in vitro microphysiological systems are developed for mimicking different disease models and to be used as drug screening assays. I will describe developed systems for investigating human cancer microenvironment and its usage in anti-cancer drug delivery. The developed system enables recreation of different aspects of cancer microenvironment with vasculature and either organ-specific cells or immune cells in addition to cancer cells. The advantages of using microfluidic systems as disease model and drug screening assay include requiring only small sample volume, minimized manual repetition and relatively fast turnout time. Overall, the microfluidic model developed can reproduce different pathological microenvironment, and can give the insights on drug efficacies for particular microenvironments.

Title to be Confirmed.
Yoshinobu Baba, Professor, Nagoya University, Japan

Title to be Confirmed.
Danilo Tagle, Director, Office of Special Initiatives, National Center for Advancing Translational Sciences at the NIH (NCATS), United States of America

Title to be Confirmed.
Anderson Shum, Professor, Department of Mechanical Engineering; Director, Advanced Biomedical Instrumentation Centre, University of Hong Kong, Hong Kong